Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative Crossover Pharmacokinetic Study of a Dietary Supplement: 600 mg of Ultra-micronized Palmitoylethanolamide (PEA) (Normast 600) Versus 600 mg of PEA in a Liposomal Formulation (AliaMed) in Healthy Subjects Following a Single Oral Dose.

NCT07804758 is registered in ClinicalTrials.gov with S&R Farmaceutici S.p.A. as lead sponsor.

NCT NCT07804758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07804758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative Crossover Pharmacokinetic Study of a Dietary Supplement: 600 mg of Ultra-micronized Palmitoylethanolamide (PEA) (Normast 600) Versus 600 mg of PEA in a Liposomal Formulation (AliaMed) in Healthy Subjects Following a Single Oral Dose.
Lead sponsor
S&R Farmaceutici S.p.A.
Phase
Not applicable
Overall status
Completed
Start date
April 13, 2026
Completion date
April 30, 2026
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liposomal encapsulation, palmitoylethanolamide, pk in healthy volunteers